Novartis buys Avidity Biosciences as part of broader spending spree
The Swiss M&A market reached record levels in 2025. Swissinfo looks at some of those deals and why they matter.
Select your language
Generated with artificial intelligence.
Listening:
Novartis buys Avidity Biosciences as part of broader spending spree
M&A transactions volumes in Switzerland exceeded $163 billion last year, mostly driven by outbound investment of pharma and the technology, media and telecom industries.
That compares with $115 billion in 2024.
In October last year Novartis said it had agreed to buy the US biotech company Avidity Biosciences for around $12 billion (CHF9.4), with the goal of accessing new therapies and boosting mid-term growth.
The transaction will strengthen Novartis’ neuroscience business with three programmes in the late development phase, according to a press release issued at the time.
The company said it will increase its annual growth for the period between 2024 and 2029 from 5 to 6%.
This is the company’s biggest acquisition in more than a decade and comes as Novartis is increasing M&A spending.
Text: vm
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.